Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Autor: Josée M. Zijlstra, Otto Visser, Gustaaf W. van Imhoff, Judith M. Roesink, Michael Schaapveld, Monique E. van Leerdam, Philip Poortmans, Augustinus D.G. Krol, Petur Snaebjornsson, Pieternella J. Lugtenburg, Cecile P.M. Janus, Richard W.M. van der Maazen, Max Beijert, Berthe M.P. Aleman, Lisanne S. Rigter, Flora E. van Leeuwen, Anna M. van Eggermond
Přispěvatelé: Hematology, CCA - Cancer Treatment and quality of life, Radiation Oncology
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
Cancer Research
Colorectal cancer
medicine.medical_treatment
Gastroenterology
0302 clinical medicine
Cancer Survivors
Interquartile range
Non-U.S. Gov't
Gastrointestinal Neoplasms
Original Research
RISK
Research Support
Non-U.S. Gov't
Hazard ratio
second malignancy
Middle Aged
Hodgkin Disease
2ND MALIGNANT NEOPLASMS
Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
Oncology
Radiology Nuclear Medicine and imaging
030220 oncology & carcinogenesis
Cohort
population characteristics
Female
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
RADIOTHERAPY
Adult
medicine.medical_specialty
gastrointestinal cancer
Research Support
survival
Young Adult
03 medical and health sciences
SDG 3 - Good Health and Well-being
Internal medicine
parasitic diseases
Journal Article
medicine
Humans
Radiology
Nuclear Medicine and imaging
Gastrointestinal cancer
Chemotherapy
CHILDHOOD-CANCER
business.industry
Clinical Cancer Research
LONG-TERM SURVIVAL
Cancer
social sciences
medicine.disease
Survival Analysis
Radiation therapy
030104 developmental biology
business
human activities
Hodgkin lymphoma
Zdroj: Cancer Medicine, 8(1), 190-199
Cancer Medicine, 8, 190-199
Cancer Medicine, 8(1), 190-199. John Wiley and Sons Ltd
Cancer Medicine, 8(1), 190-199. John Wiley & Sons Ltd.
Cancer Medicine
Cancer Medicine, 8, 1, pp. 190-199
Cancer medicine, 8(1), 190-199. Wiley
Cancer Medicine, 8(1), 190. John Wiley and Sons Ltd
Rigter, L S, Schaapveld, M, Janus, C P M, Krol, A D G, van der Maazen, R W M, Roesink, J, Zijlstra, J M, van Imhoff, G W, Poortmans, P M P, Beijert, M, Lugtenburg, P J, Visser, O, Snaebjornsson, P, van Eggermond, A M, Aleman, B M P, van Leeuwen, F E & van Leerdam, M E 2019, ' Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer ', Cancer Medicine, vol. 8, no. 1, pp. 190-199 . https://doi.org/10.1002/cam4.1922
ISSN: 2045-7634
Popis: Contains fulltext : 203188.pdf (Publisher’s version ) (Open Access) BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. METHODS: Overall and cause-specific survival of GI cancer patients in a HL survivor cohort (GI-HL, N = 104, including esophageal, gastric, small intestinal, and colorectal cancer) was compared with survival of a first primary GI cancer patient cohort (GI-1, N = 1025, generated by case matching based on tumor site, gender, age, and year of diagnosis). Cox proportional hazards regression was used for survival analyses. Multivariable analyses were adjusted for GI cancer stage, grade of differentiation, surgery, radiotherapy, and chemotherapy. RESULTS: GI-HL cancers were diagnosed at a median age of 54 years (interquartile range 45-60). No differences in tumor stage or frequency of surgery were found. GI-HL patients less often received radiotherapy (8% vs 23% in GI-1 patients, P < 0.001) and chemotherapy (28% vs 41%, P = 0.01) for their GI tumor. Compared with GI-1 patients, overall and disease-specific survival of GI-HL patients was worse (univariable hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.03-1.65, P = 0.03; and HR 1.29, 95% CI 1.00-1.67, P = 0.049, respectively; multivariable HR 1.33, 95% CI 1.05-1.68, P = 0.02; and HR 1.33, 95% CI 1.03-1.72, P = 0.03, respectively). CONCLUSIONS: Long-term overall and disease-specific survival of GI cancer in HL survivors is worse compared with first primary GI cancer patients. Differences in tumor stage, grade of differentiation, or treatment could not explain this worse survival.
Databáze: OpenAIRE
Externí odkaz: